
|Articles|April 27, 2004
VIM Trial results favor PDT for small, subfoveal minimally classic,AMD-related CNV
Verteporfin (Visudyne) photodynamic therapy (PDT) using either a reducedor standard light fluence rate appears to be beneficial for patients withrelatively small, subfoveal minimally classic CNV associated with age-relatedmacular degeneration (AMD), said Philip J. Rosenfeld, MD.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Bayer acquires Perfuse Therapeutics, partners with Iambic to expand ophthalmology and AI capabilities
2
Obstructive sleep apnea and glaucoma: What a 12.5-million-patient data set reveals
3
Memento Medicines launches with $93 million Series A to advance Tie2-activating bispecific for retinal disease
4
Meta's AI glasses for veterans: Canto-Sims, OD on closing the access gap
5


























